Peer-Review of the Phase 3 Study Moderna & NIAID Study Results: Unprecedented Accomplishment

Peer-Review of the Phase 3 Study Moderna & NIAID Study Results Unprecedented Accomplishment

The results of a Phase 3 clinical trial evaluating the COVID-19 vaccine known as mRNA-1273 were published in the peer-reviewed New England Journal of Medicine. The vaccine, co-developed by Moderna, Inc., the Cambridge, MA-based biotech company along with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National institutes of Health (NIH) was recently evaluated in the COVE trial. The peer-reviewed  findings confirm that no material safety concerns are prominent and that the vaccine, now approved under emergency authorization, shows a 94.1% efficacy rate in preventing SARS-CoV-2, the virus behind COVID-19. TrialSite echoes the authors’ conclusion that this vaccine is associated with unprecedented collaborative productivity: the pandemic led to a confluence of government, academic, medical and business interests leading to historical accomplishment in the field of vaccine development.  

This recent study was led by Lindsey R. Baden, M.D. of Brigham and Women’s Hospital in Boston, Hana M. El-Sahly, M.D. of Baylor College of Medicine in Houston, and Brandon Essink, M.D., of Meridian Clinical Research. The trial was implemented under ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee